Business Wire

New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients

Del

Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to help clinicians reduce the number of days ICU patients experience hyperoxemia while on mechanical ventilation.1 ORi, available outside the U.S., is a noninvasive and continuous parameter intended as a relative indicator of a patient’s oxygen reserve during moderate hyperoxia (partial pressure of oxygen in arterial blood [PaO2] in the range of 100 to 200 mmHg). ORi can be trended and has optional alarms to notify clinicians of changes in oxygenation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180930005016/en/

Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)

Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)

Noting that hyperoxemia can lead to patient morbidity and mortality in ICU patients, and that oxygen saturation (SpO2) cannot detect hyperoxemia, Dr. Brochant and colleagues sought to evaluate whether ORi might be useful in helping clinicians determine when to reduce the fraction of inspired oxygen (FiO2) during oxygen therapy, so as to avoid hyperoxemia. In this initial analysis, the first 131 patients in the study, whose data were collected between May 2017 and March 2018, were randomly assigned into an ORi and a control group. In the ORi group, FiO2 was reduced if ORi was > 0. In the control group, the FiO2 level was adjusted according to SpO2. Clinicians recorded blood gas results, episodes of atelectasis, and the length of time spent on mechanical ventilation, for up to 28 days. The principal point of comparison was the proportion of ventilated days with hyperoxemia.

The researchers found that the percentage of days with hyperoxemia was significantly lower in the ORi group: median 14% [interquartile range 0-31%], vs. 29% [IQR 11-50%] in the control group, p=0.005. Average daily PaO2 and FiO2 values were not significantly different between the two groups, suggesting that FiO2 was not systematically lowered in the ORi group. The average number of days without ventilation and median time spent in the ICU were also not significantly different.

The researchers concluded that the use of ORi may help clinicians reduce the percentage of days with hyperoxemia, that analysis of the full group of patients may allow assessment of its effect on the occurrence of atelectasis, and that additional studies may be useful in evaluating the impact of this monitoring on the morbidity and mortality of patients.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

@MasimoInnovates | #Masimo

Reference

  1. Brochant A, Dupre P, Gaillard T, Lemarie P, Gergaud S, and Lasocki S. “ORi pour moins d’hyperoxie en reanimation.” Proceedings from SFAR 2018, Paris, France. #R244.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  6. Estimate: Masimo data on file.
  7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo ORi. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo ORi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 10:05:00 CESTPressemelding

Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA19.6.2019 10:00:00 CESTPressemelding

Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005222/en/ Invivoscribe Headquarters - San Diego, CA (Photo: Business Wire) The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival (OS) compared to salvage chemotherapy when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay. Mutations in the FLT3 gene are among the most important driver mutations in AML. This milestone furt

BearingPoint Acquires Public Services Consultancy Prederi in the UK19.6.2019 08:50:00 CESTPressemelding

Management and technology consultancy BearingPoint made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. The acquisition supports BearingPoint’s overall growth objectives, strengthens its presence in the UK, and broadens its public service capabilities. With this transaction, two highly profitable companies join forces. Prederi provides expert advice and consultancy and serves a large number of prestigious UK public sector clients. For many years, Prederi has been generating stable revenue streams. The Prederi team now expands BearingPoint’s expertise and capabilities in one of the largest and most competitive public services markets in Europe. “With the acquisition of Prederi we are continuing our growth strategy in selected markets with consultancies that are highly focused and strongly differentiated,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Prederi's portfolio is a perfect complement to our public service strategy

HCL Technologies Selected by Cricket Australia as Digital Technology Partner19.6.2019 07:52:00 CESTPressemelding

HCL Technologies (HCL) and Cricket Australia (CA) have today announced a multi-year partnership, with HCL being chosen as the Digital Technology Partner of CA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005284/en/ HCL Technologies and Cricket Australia exchanging mementos to announce digital partnership. Standing left to right: Brad Hodge, former Australian international cricketer, & current cricket coach; Arthur Fillip, Executive Vice President - Sales Transformation & Marketing; Kevin Roberts, CEO, Cricket Australia; Swapan Johri, Corporate Vice President & Head - Asia/Pacific & Middle East Business; Belinda Clarke, Executive General Manager, Community Cricket & former captain of the Australian Women's Cricket Team (Photo: Business Wire) HCL, a leading global technology company, will help the Australian cricket’s governing body provide an elevated and immersive digital experience to cricket fans, players, partner

Sartorius Starts up Operations at Expanded Site in Puerto Rico19.6.2019 07:30:00 CESTPressemelding

After investing more than 100 million U.S. dollars, Sartorius, a leading international partner of biopharmaceutical research and the industry, started up its expanded manufacturing operations in Yauco, Puerto Rico. The U.S. market is primarily supplied from this site, given that Sartorius has been growing strongly in this marketplace at above-average rates over the past several years. “Operationally and strategically, this expansion is an important investment for us. The considerably higher production capacities created as a result now give us leeway to deliver an even wider product array directly from the region to our American customers and to implement our ambitious growth plans in the Americas,” said Sartorius Executive Board Chairman and CEO Joachim Kreuzburg to approximately 500 employees and guests at the opening ceremony on Tuesday in Yauco. The company substantially extended the plant in Puerto Rico within a construction phase of around three years, more than doubling producti

comforte AG Gives Apache Kafka a Big Data Security Boost19.6.2019 07:14:00 CESTPressemelding

comforte AG, a leading provider of enterprise data security and digital payments solutions, has announced new integration capabilities for Apache Kafka with the latest release of its Enterprise Data Protection Suite. Apache Kafka is a distributed data streaming platform that allows users to collect and examine real-time data streams from a variety of popular applications. These new capabilities enable organizations to integrate data protection methods, like tokenization or format-preserving encryption, into their Kafka environments. Anonymization and pseudonymization can be applied to sensitive data on the fly within Apache Kafka to help organizations protect information and fulfil compliance regulations. The additional capabilities cater to use cases unique to the Apache Kafka environment, especially Kafka Connect and Kafka Streams. The release will be making its debut at Whitehall Media’s Big Data Analytics Conference in London, the industry event showcasing the latest Big Data Analy